SOURCE: SciClone Pharmaceuticals, Inc.

December 13, 2005 16:30 ET

SciClone to Host a Conference Call December 14, 2005 to Discuss ZADAXIN Phase 3 Hepatitis C Results and Interim Phase 2 Malignant Melanoma Data

SAN MATEO, CA -- (MARKET WIRE) -- December 13, 2005 -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will report ZADAXIN® phase 3 hepatitis C results and interim phase 2 malignant melanoma data before the market opens on Wednesday, December 14, 2005 and host a conference call that morning at 9:00 a.m. Eastern Time to discuss these results. The conference call will contain forward-looking statements.

DATE:   Tuesday, December 14, 2005

TIME:   9:00 a.m. ET (6:00 a.m. PT)

WEBCAST:  live call and replay accessible at

LIVE CALL:   800-819-9193 (U.S./Canada)
             913-981-4911 (international)

REPLAY:      888-203-1112 (U.S./Canada)
             719-457-0820 (international)
             passcode: 8647825
About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in two phase 3 hepatitis C clinical trials in the United States and one hepatitis C triple therapy clinical trial in Europe. ZADAXIN also is being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers. The company's other principal drug development candidate is SCV-07, currently in phase 1 development, which is being evaluated for the treatment of viral and other infectious diseases. For more information about SciClone, visit

Contact Information

  • Corporate information contact:
    Becky Horner
    Investor Relations
    SciClone Pharmaceuticals, Inc.